{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"A DLT is defined as Grade 4 or greater anemia or neutropenia exceeding 5 days duration, thrombocytopenia requiring transfusion, or Grade 3 or greater nonhematologic toxicity possibly, probably, or definitely related to the investigational therapy excluding alopecia during Cycle 1 of therapy.","groups":[{"description":"Phase I Dose Level 1 Mithramycin 60 mcg/kg\n\nMithramycin: Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses..","id":"OG000","title":"Phase I Dose Level 1 Mithramycin 60 mcg/kg"},{"description":"Phase I Dose Level -1 Mithramycin 60 mcg/kg followed by Mithramycin 30 mcg/kg\n\nMithramycin: Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses.","id":"OG001","title":"Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Cycle 1","title":"Number of Participants With a Dose-limiting Toxicity (DLT)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}